Lexaria's Phase 1b Study Achieves Primary Endpoint

Lexaria Bioscience Corp. successfully achieved the primary endpoint in its Phase 1b study, GLP-1-H24-4, demonstrating the efficacy of its DehydraTECH-semaglutide formulation. The study indicated a 48% reduction in overall side effects and a 55% reduction in gastrointestinal side effects compared to Rybelsus®. These results support the formulation's potential as a safer alternative in drug delivery.

Lexaria's recent financing activities, raising $7.5 million, have secured adequate funds for prospective development opportunities in 2026. The study involved 126 participants, evaluating safety and efficacy across multiple treatment arms. Results highlighted that DehydraTECH-semaglutide demonstrated superior safety, with a significant reduction in adverse events compared to the control.

Continued evaluation of this formulation, potentially including the SNAC ingredient, is planned to further enhance its therapeutic profile. Lexaria aims to leverage these positive findings in collaboration with its pharmaceutical partners.